Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. DAL
10. TMUS

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 1c

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

February 5, 2018 6:59 AM EST

Increases Fourth Quarter Revenues 4% to $5.4 Billion, 7% for Full Year to $20.8 Billion Posts Fourth Quarter GAAP Loss Per Share of $1.42, Driven by Tax Reform Charges, Non-GAAP EPS of $0.68 Achieves Important Clinical and Regulatory Milestones in Oncology Opdivo Plus Yervoy Demonstrates Superior Progression-Free Survival vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients with High Tumor Mutation Burden in CheckMate -227 Opdivo Approved in the U.S. for Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease... More